Skip to Content
Merck
  • [Experience in the pre-hospital treatment of acute coronary syndrome with metoprolol succinate].

[Experience in the pre-hospital treatment of acute coronary syndrome with metoprolol succinate].

Klinicheskaia meditsina (2013-06-26)
A L Vertkin, S N Morozov, A I Fedorov
ABSTRACT

Patients with acute coronary syndrome and elevated ST segment in the pre-hospital phase were treated with metoprolol succinate (MS) and thrombolytic therapy. Severe and moderate pain decreased by 54.1 and 16.1% respectively within 60 min after MS intake. Systolic (SAP) and diastolic (DAP) arterial pressure dropped by 35.7 and 16.8 mmHg during the same period. The heart rate (HR) decreased by 25.1 beats/min. 21.8 and 25.3% of the patients showed positive dynamics of ST segment 90 and 180 min after intake of MS. The height of the ST segment was normal in 18.4 and 31.0% of the patients respectively. No cases of external heart rupture were documented at autopsy whereas it was a cause of death in 39.1% of the patients given standard thrombolytic therapy. It is concluded that the use of MS starting from the pre-hospital stage in patients with acute coronary syndrome decreases pain intensity. HR, DAP and SAP and helps to prevent heart rupture.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
(±)-Metoprolol (+)-tartrate salt, ≥98% (titration), powder
Metoprolol tartrate, European Pharmacopoeia (EP) Reference Standard
Supelco
Metoprolol Tartrate, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Metoprolol tartrate solution, 1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®